OPM's subsidiary passes EU QP audit

OPM's wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., recently successfully passed the European Union Quality Authorised Person (QP) audit and received a compliance audit report. This marks that Silun Biotechnology's quality management system meets the requirements of EU GMP regulations, providing assurance for its research and production services in the field of macromolecular biopharmaceuticals, and laying the foundation for expanding into international markets such as the EU

CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up

CRO concept stocks fluctuated upward, Jiuzhou Pharma hit the daily limit, APELOA rose over 5%, JOINN, Chemspec, OPM, and Haoyuan Pharma followed suit

Zhitong A-share lock-up release overview | September 2

On September 2nd, a total of 6 listed companies had their restricted shares unlocked, with a total market value of approximately 5.525 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares FOTON 600166 Additional A Shares Original Shareholders Allocation Listed 1.429 billion ITG 600755 Equity Incentive Restricted Circulation 396,100 GEM 002340 Equity Incentive Restricted Circulation 8.7545 million VENUSTECH 002439 Equity Incentive Restricted Circulation 988,700 NJF 301296 Pre-issuance Shares Restricted Circulation 17.136 million OPM 688293 3.61394 million

OPM: Expected net profit of approximately 37 million yuan in the first half of the year, a year-on-year increase of 53.28%

OPM announced that it expects to achieve a net profit of approximately 37 million yuan attributable to the owners of the parent company in the first half of 2025, representing a year-on-year increase of 53.28%. During the reporting period, the company's product business segment saw significant revenue growth, with a year-on-year increase of over 25%, and more than 50% growth in the second quarter. The growth in performance is mainly attributed to the company's continuous R&D innovation and market expansion in the field of cell culture products, with products gaining wide recognition in both domestic and international markets

The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suit